 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...9596979899100101102103104105...132133» |
- |||| amcenestrant (SAR439859) / Sanofi
Enrollment open, Combination therapy, Monotherapy, Metastases: AMEERA-1: Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 26, 2017
P1/2, N=156, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting
- | everolimus / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas (clinicaltrials.gov) - Sep 25, 2017
P1/2, N=118, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2018 --> Dec 2018
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (clinicaltrials.gov) - Sep 25, 2017
P2, N=306, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jul 2018 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Sep 2017 | Trial primary completion date: Jul 2020 --> Jan 2021
- | Herceptin (trastuzumab) / Roche
Journal: Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. (Pubmed Central) - Sep 21, 2017
Mutational burden in heavily treated trastuzumab-resistant Her2-positive metastatic breast cancer is highly variable and not directly correlated with outcome. Activation of the MAPK/ERK pathway through mutations in EGFR, BRAF or KIT may mediate resistance to trastuzumab.
- | everolimus / Generic mfg., Torisel (temsirolimus) / Pfizer
Biomarker, Review, Journal: Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. (Pubmed Central) - Sep 21, 2017
Challenges to the therapeutic effectiveness of some PI3K inhibitors include the absence of reliable and effective biomarkers, their limited efficacy as single agents, insufficient development of rational therapeutic combinations, the use of schedules with a variety of off-target effects, and suboptimal therapeutic exposures. Therefore, with regard to PI3K inhibitors currently in late-stage clinical trials, the identification of appropriate biomarkers of efficacy and the development of optimal combination regimens and dosing schedules are likely to be important for graduation into clinical practice.
- | letrozole / Generic mfg., everolimus / Generic mfg.
New P2/3 trial: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation (clinicaltrials.gov) - Sep 17, 2017
P2/3, N=1, Active, not recruiting, Sponsor: Greater Baltimore Medical Center
- ||||| amcenestrant (SAR439859) / Sanofi
New P1/2 trial, Combination therapy, Monotherapy, Metastases: AMEERA-1: Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 14, 2017
P1/2, N=156, Not yet recruiting, Sponsor: Sanofi
- |||| everolimus / Generic mfg., fulvestrant / Generic mfg.
Trial completion, Metastases: Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI (clinicaltrials.gov) - Sep 14, 2017
P2, N=131, Completed, Sponsor: PrECOG, LLC.
Therefore, with regard to PI3K inhibitors currently in late-stage clinical trials, the identification of appropriate biomarkers of efficacy and the development of optimal combination regimens and dosing schedules are likely to be important for graduation into clinical practice. Active, not recruiting --> Completed
- || Trial primary completion date, Gene Expression Profile, IO biomarker, Biopsy, Post-transplantation: Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens (clinicaltrials.gov) - Sep 13, 2017
P=N/A, N=88, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: May 2017 --> May 2020
- || everolimus / Generic mfg., fulvestrant / Generic mfg.
Trial primary completion date, Metastases: Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI (clinicaltrials.gov) - Sep 12, 2017
P2, N=131, Active, not recruiting, Sponsor: PrECOG, LLC.
Trial primary completion date: May 2017 --> May 2020 Trial primary completion date: Oct 2017 --> Mar 2017
- everolimus / Generic mfg.
Trial primary completion date: SAGE: Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (clinicaltrials.gov) - Sep 11, 2017
P2, N=43, Recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Oct 2017 --> Mar 2017 Trial primary completion date: Jul 2017 --> Jul 2019
- |||| Herceptin (trastuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: BOLERO-1: Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Sep 11, 2017
P3, N=719, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2017 --> Jul 2019 Trial primary completion date: May 2018 --> Oct 2017
- | Biomarker, Review, Journal: Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. (Pubmed Central) - Sep 8, 2017
Most recently, several new drugs including nivolumab, cabozantinib, and a combination of lenvatinib and everolimus have demonstrated acceptable toxicity and significantly improved overall survival, but evidence-based guidelines for sequencing of the approved treatment options and treatment selection based on biomarkers are still missing...Several ongoing clinical trials are evaluating sequencing, timing of cytoreductive nephrectomy, combinations of immunotherapies and targeted therapies as well as selection of the best systemic treatment. Personalized treatment based on tumor profiling is one of the brightest spots on the horizon.
- |||| Trial completion: MANDELA: A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (clinicaltrials.gov) - Sep 7, 2017
P4, N=185, Completed, Sponsor: Novartis Pharmaceuticals
Personalized treatment based on tumor profiling is one of the brightest spots on the horizon. Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Biomarker, Enrollment open, Enrollment change, Trial primary completion date: PEARL: Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women (clinicaltrials.gov) - Sep 5, 2017
P2, N=46, Recruiting, Sponsor: Jules Bordet Institute
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=130 --> 46 | Trial primary completion date: Oct 2016 --> Jun 2018
- ||| vistusertib (AZD2014) / AstraZeneca
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: MANTA: A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer (clinicaltrials.gov) - Aug 28, 2017
P2, N=333, Active, not recruiting, Sponsor: Queen Mary University of London
Active, not recruiting --> Recruiting | N=130 --> 46 | Trial primary completion date: Oct 2016 --> Jun 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2019
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Cabozantinib use in renal cell carcinoma. (Pubmed Central) - Aug 26, 2017
This agent's toxicity profile is similar to those of other multikinase inhibitors approved to treat RCC. This review will explore cabozantinib's pharmacologic and safety profile and its preclinical and clinical activity in RCC.
- |||||| everolimus / Generic mfg.
Enrollment open: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Aug 24, 2017
P3, N=355, Recruiting, Sponsor: Novartis Pharmaceuticals
This review will explore cabozantinib's pharmacologic and safety profile and its preclinical and clinical activity in RCC. Active, not recruiting --> Recruiting
- dactolisib (RTB101) / Adicet Bio
Phase classification, Enrollment change, Trial termination, Trial primary completion date, Metastases: Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 23, 2017
P1b, N=19, Terminated, Sponsor: University of Cincinnati
Active, not recruiting --> Recruiting Phase classification: P1/2 --> P1b | N=54 --> 19 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Feb 2014; funding
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: IMPROVE: Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (clinicaltrials.gov) - Aug 23, 2017
P4, N=77, Active, not recruiting, Sponsor: iOMEDICO AG
Phase classification: P1/2 --> P1b | N=54 --> 19 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Feb 2014; funding Recruiting --> Active, not recruiting | N=192 --> 77 | Trial primary completion date: Dec 2018 --> Aug 2017
- || Simulect (basiliximab) / Novartis
Clinical: TRANSFORMt: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (clinicaltrials.gov) - Aug 22, 2017
P4, N=2037, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=192 --> 77 | Trial primary completion date: Dec 2018 --> Aug 2017 Trial primary completion date: Jan 2018 --> Feb 2017
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Enrollment closed, Combination therapy: Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Aug 22, 2017
P1, N=26, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jan 2018 --> Feb 2017 Recruiting --> Active, not recruiting
- |||| Kisqali (ribociclib) / Novartis
Enrollment open, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Aug 22, 2017
P2, N=76, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | everolimus / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. (Pubmed Central) - Aug 20, 2017
P1
These findings suggest that drugs that target the PI3K-mTORC pathway add benefit when combined with standard R-CHOP. The everolimus with R-CHOP regimen should be tested against standard R-CHOP alone in a randomised trial, to support the benefits of this novel combination noted in this study.
- || letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Aug 18, 2017
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
The everolimus with R-CHOP regimen should be tested against standard R-CHOP alone in a randomised trial, to support the benefits of this novel combination noted in this study. Trial primary completion date: Jul 2017 --> Jul 2018
- | everolimus / Generic mfg., Sutent (sunitinib) / Pfizer
Biomarker, Review, Journal: Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. (Pubmed Central) - Aug 17, 2017
What new molecular targets can be clinically exploited? A tight integration between basic and clinical research is needed to further advance the field of NETs.
- |||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria (clinicaltrials.gov) - Aug 15, 2017
P4, N=171, Completed, Sponsor: Helio Tedesco Silva Junior
A tight integration between basic and clinical research is needed to further advance the field of NETs. Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Journal: Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. (Pubmed Central) - Aug 12, 2017
P2
Active, not recruiting --> Completed Prophylactic use of dexamethasone oral solution substantially reduced the incidence and severity of stomatitis in patients receiving everolimus and exemestane and could be a new standard of oral care for patients receiving everolimus and exemestane therapy.
- | everolimus / Generic mfg.
Trial primary completion date: Everolimus Post Orthotopic Liver Transplant (clinicaltrials.gov) - Aug 10, 2017
P2, N=50, Recruiting, Sponsor: Tomoaki Kato
Prophylactic use of dexamethasone oral solution substantially reduced the incidence and severity of stomatitis in patients receiving everolimus and exemestane and could be a new standard of oral care for patients receiving everolimus and exemestane therapy. Trial primary completion date: Oct 2016 --> Jun 2018
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Trial primary completion date: Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Aug 10, 2017
P1, N=26, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Oct 2016 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Feb 2020 --> Feb 2015
- || sapanisertib (CB-228) / Calithera
Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer (clinicaltrials.gov) - Aug 10, 2017
P1b/2, N=128, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Feb 2020 --> Feb 2015 Trial primary completion date: Jun 2017 --> Jan 2018
- | Review, Journal: Advanced Hepatocellular Cancer: the Current State of Future Research. (Pubmed Central) - Aug 10, 2017
Currently, sorafenib remains the only established systemic therapy proven to increase the overall survival of patients with advanced disease...Having reached somewhat of an impasse in terms of drug development in hepatocellular carcinoma, enthusiasm in the field has moved toward innovative approaches such as molecular characterization and immunotherapy in an attempt to impact survival. This review highlights the current endeavors in terms of experimental research for patients with advanced hepatocellular carcinoma.
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial, Combination therapy: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Aug 9, 2017
P1/2, N=132, Not yet recruiting, Sponsor: Eisai Inc.
- |||| everolimus / Generic mfg., vinorelbine tartrate / Generic mfg.
Trial completion, Trial primary completion date, Combination therapy, Monotherapy, Metastases: VicTORia: Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (clinicaltrials.gov) - Aug 9, 2017
P2, N=139, Completed, Sponsor: AIO-Studien-gGmbH
This review highlights the current endeavors in terms of experimental research for patients with advanced hepatocellular carcinoma. Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Oct 2016
- || letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) - Aug 9, 2017
P2, N=74, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Oct 2016 Trial primary completion date: Dec 2016 --> Jun 2017
- | Enrollment change: Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients (clinicaltrials.gov) - Aug 7, 2017
P=N/A, N=0, Withdrawn, Sponsor: University of Kentucky
Trial primary completion date: Dec 2016 --> Jun 2017 N=60 --> 0
- | everolimus / Generic mfg.
Trial initiation date: CHONRAD: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (clinicaltrials.gov) - Aug 7, 2017
P2, N=57, Suspended, Sponsor: Centre Leon Berard
N=60 --> 0 Initiation date: Mar 2014 --> Aug 2014
- temozolomide / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Aug 4, 2017
P1/2, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Mar 2014 --> Aug 2014 Trial primary completion date: Jul 2016 --> Nov 2017
- | Enrollment change, Trial termination, Trial primary completion date: Personalized Targeted Inhibitors Treatment in Renal Cell Cancer (clinicaltrials.gov) - Aug 3, 2017
P2, N=4, Terminated, Sponsor: The University of Texas Health Science Center, Houston
Trial primary completion date: Jul 2016 --> Nov 2017 N=100 --> 4 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2017; Loss of laboratory performing molecular analysis
- | everolimus / Generic mfg.
Biomarker, Journal: Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. (Pubmed Central) - Aug 3, 2017
N=100 --> 4 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2017; Loss of laboratory performing molecular analysis This analysis, although exploratory, suggests that patients with human epidermal growth factor receptor 2-positive advanced breast cancer having tumors with PIK3CA mutations, PTEN loss, or hyperactive PI3K pathway could derive PFS benefit from everolimus.
- | New P2 trial: Efficacy and Safety of Precision Therapy in Refractory Tumor (clinicaltrials.gov) - Aug 2, 2017
P2, N=60, Recruiting, Sponsor: Baodong Qin
- |||| everolimus / Generic mfg.
Trial primary completion date, Metastases: Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT (clinicaltrials.gov) - Aug 2, 2017
P3, N=200, Recruiting, Sponsor: Comprehensive Support Project for Oncology Research
This analysis, although exploratory, suggests that patients with human epidermal growth factor receptor 2-positive advanced breast cancer having tumors with PIK3CA mutations, PTEN loss, or hyperactive PI3K pathway could derive PFS benefit from everolimus. Trial primary completion date: Nov 2017 --> Mar 2019
- | everolimus / Generic mfg.
Journal: Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series. (Pubmed Central) - Jul 29, 2017
In this heavily pre-treated, advanced sarcoma population, the addition of mTOR inhibition to VEGFRi based therapy resulted in a clinical benefit for a subset of patients. Prospective studies will be needed to verify these results.
- | carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Jul 28, 2017
P1/2, N=35, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Prospective studies will be needed to verify these results. Trial primary completion date: Jun 2017 --> Dec 2017
- | everolimus / Generic mfg.
Journal: Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. (Pubmed Central) - Jul 26, 2017
The field of NETs has been transformed from one dominated by limited treatment options to one characterized by an increasing number of therapeutic agents and active clinical trials. Navigating the current therapeutic algorithm may be challenging, and requires an understanding both of the heterogeneity of NETs and of characteristics that are shared by NETs across tumor subtypes.
- everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Metastases: First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov) - Jul 26, 2017
P2, N=36, Active, not recruiting, Sponsor: Matthew Galsky
Navigating the current therapeutic algorithm may be challenging, and requires an understanding both of the heterogeneity of NETs and of characteristics that are shared by NETs across tumor subtypes. Trial primary completion date: Jun 2017 --> Oct 2017
- | everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Trial primary completion date, Post-transplantation: Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function (clinicaltrials.gov) - Jul 25, 2017
P3, N=390, Recruiting, Sponsor: Poitiers University Hospital
Trial primary completion date: Jun 2017 --> Oct 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- | Ibrance (palbociclib) / Pfizer, everolimus / Generic mfg., fulvestrant / Generic mfg.
Biomarker, Journal: Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. (Pubmed Central) - Jul 24, 2017
The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates.
- | everolimus / Generic mfg.
Enrollment closed, Enrollment change, IO biomarker: Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas (clinicaltrials.gov) - Jul 24, 2017
P, N=5, Active, not recruiting, Sponsor: New York University School of Medicine
Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates. Recruiting --> Active, not recruiting | N=51 --> 5
- ||| Mekinist (trametinib) / Novartis, BeiGene
Enrollment closed, Trial primary completion date: GSK1120212 Rollover Study (clinicaltrials.gov) - Jul 24, 2017
P2, N=250, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | N=51 --> 5 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Aug 2017